Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of ASP2998 as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1b/2 Study of ASP2998 as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASP 2998 (Primary) ; Carboplatin; Enfortumab vedotin; Pembrolizumab
  • Indications Adenocarcinoma; Bladder cancer; Carcinoma; Gastric cancer; HER2 negative breast cancer; Non-small cell lung cancer; Oesophageal cancer; Pelvic cancer; Renal cancer; Solid tumours; Transitional cell carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Astellas Pharma Global Development

Most Recent Events

  • 18 May 2026 According to Astellas Pharma media release, company will present Poster Presentation from this study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 - June 2 in Chicago May 30, 2026, 1:30 PM-4:30 PM CDT
  • 29 Jan 2026 Status changed from not yet recruiting to recruiting.
  • 23 Dec 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top